RECURRENT PROSTATE CANCER
Clinical trials for RECURRENT PROSTATE CANCER explained in plain language.
Never miss a new study
Get alerted when new RECURRENT PROSTATE CANCER trials appear
Sign up with your email to follow new studies for RECURRENT PROSTATE CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Could a depression drug fight prostate cancer?
Disease control CompletedThis phase 2 trial tested phenelzine sulfate (Nardil), an antidepressant, in 26 men with prostate cancer that returned after initial treatment but hadn't spread. The goal was to see if the drug could lower PSA levels, a marker of cancer activity. Researchers measured how many pat…
Matched conditions: RECURRENT PROSTATE CANCER
Phase: PHASE2 • Sponsor: University of Southern California • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Could an immunotherapy drug replace hormone therapy for some prostate cancers?
Disease control CompletedThis phase 2 trial tested the immunotherapy drug nivolumab (Opdivo) in 8 men whose prostate cancer had returned after surgery or radiation, shown by rising PSA levels. The men had specific genetic changes (MMR deficiency or CDK12 alteration) that might make their cancers more sen…
Matched conditions: RECURRENT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Grape extract shows promise for easing fatigue in prostate cancer patients
Symptom relief CompletedThis study tested whether a supplement made from muscadine grapes could reduce fatigue and improve quality of life in 106 men with prostate cancer who were already receiving hormone therapy (androgen deprivation therapy). Participants took either the grape extract or a placebo fo…
Matched conditions: RECURRENT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Wake Forest University Health Sciences • Aim: Symptom relief
Last updated Jun 27, 2026 12:02 UTC